SPCC (Sharing Progress in Cancer Care) shared on LinkedIn:
“How can clinicians effectively balance recurrence risk, treatment efficacy, and quality of life in early HR+/HER2− breast cancer?
Chemotherapy de-escalation is changing clinical strategies, driven by emerging evidence on CDK4/6 inhibitors combined with endocrine therapy, including ribociclib.
Join us live on Wednesday, 18 November 2026 (16:00 CET) for ‘Chemotherapy De-escalation and CDK4/6 Inhibition’.
Led by discussant François-Clément Bidard (Institut Curie, FR) and expert speaker Jessica Tao (Johns Hopkins School of Medicine, US), the session will translate recent trial data into practical clinical decision-making, patient selection strategies, and multidisciplinary care.
This activity is supported by unrestricted funding from Novartis.”
You can also read: From TAILORx to OPTIMA: Genomic Testing Expands Chemotherapy De-escalation in Higher-Risk HR-Positive Breast Cancer
